Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Thoracic (Lung/Pleura)

Quantitative 18F-FDG PET/CT for response evaluation after lung ablation for treatment of primary or metastatic lung tumors

Moein Moradpour, Omar Al-Daoud, Sedra Abou Ali Mhana, Thomas Werner, Abass Alavi and Stephen Hunt
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 241588;
Moein Moradpour
1University of Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Omar Al-Daoud
1University of Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sedra Abou Ali Mhana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Werner
2Hospital of the University of Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abass Alavi
1University of Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Hunt
1University of Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

241588

Introduction: The objective of this study was to investigate the potential of PET imaging to monitor tumor metabolic changes post-lung ablation treatment and to determine a correlation between PET results and tumor recurrence. The study also aimed to identify markers that could be used to predict the success of such interventions.

Methods: In this IRB-approved retrospective study, we examined patients who underwent lung tumor ablation for neoplasms between January 2014 and January 2022. Patients were identified using the Hi-IQ database, and clinical data were obtained from medical records. The imaging data from institutional PACS was analyzed descriptively to evaluate the utility of FDG-PET/CT in monitoring course progression following ablation. An adaptive contrast-oriented thresholding algorithm was applied to calculate the uncorrected SUVmean, partial volume correction (PVC) SUVmean, and Total lesion glycolysis (TLG). An automatic adaptive thresholding method (ROVER, ABX GmbH) was used to determine the metabolically active volume(MAV) of lesions.

Results: A study reviewed 42 lung tumor patients aged 30-89, with a slight female majority. Metastatic tumors, mostly from colorectal cancer, were present in 23 patients, while the rest had primarily non-small cell lung cancer. After lung ablation, PET scans indicated a reduction in the SUV mean for 63% of the participants. According to PERCIST, 37.5% achieved complete response, 18.7% had partial response, 18.7% remained stable, and 25% showed disease progression. Post-treatment, 63% saw a decrease in Total Lesion Glycolysis (TLG), with an average drop from 48.1 to 40.5, while 37.5% experienced an increase in TLG, averaging a change of -7.6.

Conclusions: The study confirms that FDG PET/CT is effective in evaluating lung tumor shrinkage post-ablation, with many patients showing reduced SUV means. PERCIST criteria indicated successful responses in several cases, and TLG analysis revealed both decreases and mixed outcomes, highlighting PET/CT's role in guiding patient treatment strategies.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 65, Issue supplement 2
June 1, 2024
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Quantitative 18F-FDG PET/CT for response evaluation after lung ablation for treatment of primary or metastatic lung tumors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Quantitative 18F-FDG PET/CT for response evaluation after lung ablation for treatment of primary or metastatic lung tumors
Moein Moradpour, Omar Al-Daoud, Sedra Abou Ali Mhana, Thomas Werner, Abass Alavi, Stephen Hunt
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241588;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Quantitative 18F-FDG PET/CT for response evaluation after lung ablation for treatment of primary or metastatic lung tumors
Moein Moradpour, Omar Al-Daoud, Sedra Abou Ali Mhana, Thomas Werner, Abass Alavi, Stephen Hunt
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241588;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Radiolabeled PD-L1 targeted nanobody 68Ga-THP-APN09 in predicting the efficacy of neoadjuvant immunotherapy combined chemotherapy in resectable non-small cell lung cancer
  • [68Ga]Ga-satoreotide trizoxetan uptake in high grade neuroendocrine lung cancers
  • The role of [18F]FDG PET/CT in pulmonary microwave ablation
Show more Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Thoracic (Lung/Pleura)

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire